Compare Davita Inc (DVA) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs MobilEye Global Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while MobilEye Global Inc trades at $8.92 (market cap $7.44B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| DVA | MBLY | |
|---|---|---|
Market Cap | $11.72B | $7.44B |
Sector | Health | Technology |
52-Week High | $240.96 | $15.54 |
52-Week Low | $103.87 | $6.56 |
Enterprise Value | $24.44B | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Mobileye Global (MBLY) trades at $8.73, up 3.68% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 61.5% buy ratings and an $11.40 consensus target, representing 30.6% upside potential. Recent Q2 2026 earnings beat expectations with $0.19 EPS versus $0.06 estimate, while the company faces leadership transition as founder Amnon Shashua steps down after 27 years.
The investment case balances strong revenue growth and market positioning in autonomous driving technology against significant profitability challenges and leadership uncertainty. While the company benefits from expanding partnerships like the Stellantis ADAS deal, investors must weigh the -201.49% net margin and negative cash flow projections for 2026 against the substantial upside potential indicated by analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
